Tracks outcomes of people with relapsed myeloma treated with teclistamab or talquetamab
Describes use of teclistamab or talquetamab in adults with relapsed myeloma outside trials.
Key facts
- Who runs it
- Janssen-Cilag Ltd.
- Where
- Birmingham, London, and Wolverhampton, United KingdomSee the 4 sitesAlso in 10 other countries, 64 sites
- Trial code
- Registry title
- A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
- Status
- Recruiting
- People taking part
- 900 people, planned
- Started
- 18 Dec 2023
- Planned end
- 24 Sept 2026
- Type of study
- Observational, 4 groups
- Treatments tested
- Teclistamab
- Talquetamab
- Record updated
- 28 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with multiple myeloma who have already been treated with teclistamab or talquetamab outside of a clinical trial.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- A documented diagnosis of multiple myeloma.
- Earlier treatment
- Must have received at least one dose of teclistamab or talquetamab. The first dose must fall within the dates set for the cohort. Treatment given as part of an interventional clinical trial does not count.
Main reasons for not taking part
- Received teclistamab as part of an interventional clinical trial (REALiTEC cohorts)
- Received talquetamab as part of an interventional clinical trial (REALiTAL cohort)
- Received teclistamab through a Janssen pre-approval access program (REALiTEC Cohort 2 and Cohort 3)
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Have a documented diagnosis of multiple myeloma
- Received the first dose of teclistamab on or before 31 December 2022, regardless of the duration of teclistamab treatment (REALiTEC cohort 1) OR Received the first dose of teclistamab from 01 January 2023 to 31 December 2024, inclusive, regardless of the duration of teclistamab treatment (REALiTEC cohort 2) OR Received the first dose of teclistamab from 01 January 2025 to 31 December 2025, inclusive, regardless of the duration of teclistamab treatment (REALiTEC cohort 3) OR Received the first dose of talquetamab on or before 31 December 2023, regardless of the duration of talquetamab treatment (REALiTAL cohort). Participants who received both teclistamab \& talquetamab can be included in both REALiTEC and REALiTAL cohorts
- Received at least one dose of teclistamab/talquetamab
- Provision of a patient-signed informed consent form (ICF), or an ICF waiver for deceased patients as applicable based on country/site-specific requirements
Who cannot take part
- To be excluded from REALiTEC cohorts if received teclistamab as part of an interventional clinical trial
- To be excluded from REALiTAL cohort if received talquetamab as part of an interventional clinical trial
- Participants who have received teclistamab as part of a Janssen pre-approval access program are excluded from the REALiTEC Cohort 2 and REALiTEC Cohort 3
Where in United Kingdom
Also in 10 other countries, 64 sites
- Queen Elizabeth HospitalBirmingham, United KingdomTaking people
- University College HospitalLondon, United KingdomTaking people
- Guys and St Thomas NHS Foundation TrustLondon, United KingdomNo longer taking part
- The Royal Wolverhampton Hospitals NHS Trust - New Cross HospWolverhampton, United KingdomTaking people
About the trial
What the trial wants to find out
The purpose of this study is to describe the use of teclistamab/talquetamab in the treatment of patients with RRMM outside of clinical trials.
The 4 groups in the trial
- Participants with Relapsed/Refractory Multiple Myeloma (RRMM): Teclistamab Cohort 1
Participants with RRMM who received at least one dose of teclistamab outside of clinical trials on or before 31 December 2022 will be enrolled in the study. The data available from the medical records of each enrolled participant will be the collected to describe the use of teclistamab.
Treatment: Teclistamab
- Participants with Relapsed/Refractory Multiple Myeloma (RRMM): Teclistamab Cohort 2
Participants with RRMM who received at least one dose of teclistamab outside of clinical trials from 01 January 2023 to 31 December 2024, inclusive will be enrolled in the study. The data available from the medical records of each enrolled participant will be the collected to describe the use of teclistamab.
Treatment: Teclistamab
- Participants with RRMM: Teclistamab Cohort 3
Participants with RRMM who received at least one dose of teclistamab outside of clinical trials from 01 January 2025 to 31 December 2025, inclusive will be enrolled in the study. The data available from the medical records of each enrolled participant will be the collected to describe the use of teclistamab.
Treatment: Teclistamab
- Participants with RRMM: Talquetamab Cohort
Participants with RRMM who received at least one dose of talquetamab outside of clinical trials on or before 31 December 2023 will be enrolled in the study. The data available from the medical records of each enrolled participant will be collected to describe the use of talquetamab.
Treatment: Talquetamab
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- 64007957MMY4004: 64007957MMY4004 - REALiTEC
- Plain-language title
- Tracks outcomes of people with relapsed myeloma treated with teclistamab or talquetamabGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 28 August 2026